BAK vs GEVO: stock comparison and AI forecast
Braskem Sa (BAK) and Gevo, Inc. (GEVO) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
BAK Braskem Sa
- Market Cap
- $462M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
- NO CURRENT FORECAST
GEVO Gevo, Inc.
- Market Cap
- $299M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
- NO CURRENT FORECAST
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- BAK is 1.5 times larger than GEVO by market capitalization ($462M against $299M).
- Both companies share the SEC industry classification Industrial Organic Chemicals.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | BAK | GEVO |
|---|---|---|
| Market Cap | $462M | $299M |
| P/B Ratio | – | 1.10x |
| EPS | – | $-0.90 |
| Book Value/Share | – | $1.10 |
| Revenue/Share | – | $0.72 |
| FCF/Share | – | $-0.23 |
Profitability & Margins
| Metric | BAK | GEVO |
|---|---|---|
| ROE | – | -77.9% |
| ROA | – | -43.4% |
| ROIC | – | -40.3% |
| Gross Margin | – | 51.2% |
| Operating Margin | – | -102.8% |
| Net Margin | – | -119.9% |
| EBT Margin | – | -100.0% |
| Tax Rate | – | -0.0% |
Financial Health
| Metric | BAK | GEVO |
|---|---|---|
| Current Ratio | – | 2.70x |
| Quick Ratio | – | 2.19x |
| D/E Ratio | – | 0.77x |
| Financial Leverage | – | 1.80x |
| Interest Coverage | – | -33.8x |
| Working Capital | – | $64M |
Cash Flow
| Metric | BAK | GEVO |
|---|---|---|
| Operating Cash Flow | – | -$16M |
| Free Cash Flow | – | -$57M |
| Capital Spending | – | -$40M |
| FCF/Sales | – | -31.9% |
| CapEx/Sales | – | 22.8% |
Operational Efficiency
| Metric | BAK | GEVO |
|---|---|---|
| Asset Turnover | – | 0.36x |
| Receivables Turnover | – | 14.8x |
| Inventory Turnover | – | 4.5x |
| Fixed Assets Turnover | – | 0.8x |
| Days Sales Outstanding | – | 25 days |
| Days Inventory | – | 81 days |
| Payables Period | – | 33 days |
| Cash Conversion Cycle | – | 73 days |
Income Statement
| Metric | BAK | GEVO |
|---|---|---|
| Total Revenue | – | $178M |
| Operating Income | – | -$182M |
| Net Income | – | -$213M |
| R&D Expense | – | $4M |
| Cost of Goods Sold | – | $87M |
Dividend & Shareholder Information
| Metric | BAK | GEVO |
|---|---|---|
| Shares Outstanding | 399M | 247M |
BAK vs GEVO: stock comparison and AI forecast
Which is bigger, BAK or GEVO?
BAK is 1.5 times larger than GEVO by market capitalization ($462M against $299M).
Which one does Intratio's AI model rank higher, BAK or GEVO?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.